Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Date:7/31/2008

- Conference Call Today at 5:00 p.m. Eastern Time -

SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the second quarter ended June 30, 2008.

"Our strategy and focus are to develop picoplatin as an oncology platform compound addressing multiple indications, combinations and formulations. Our accomplishments during the second quarter are consistent with this objective," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We are on track to commercialize picoplatin for the treatment of small cell lung cancer (SCLC) in 2010. We presented data at the American Society of Clinical Oncology (ASCO) Annual Meeting in June, illustrating the platform potential of picoplatin in multiple solid tumor indications, including metastatic colorectal cancer (CRC), hormone refractory prostate cancer (HRPC) and ovarian cancer. Data from these trials could support future trials and may be of significant interest to potential partners. We are building a comprehensive strategy to direct our clinical development plan for further development of picoplatin in a wide range of tumor types."

Second Quarter and Recent Highlights

Picoplatin Clinical Development Program

-- Small Cell Lung Cancer: Presented final data in April from our Phase 2 trial of picoplatin in SCLC at the International Association for the Study of Lung Cancer and the European Society for Medical Oncology's 1st European Lung Cancer Conference. Final efficacy results confirmed previously announced interim results showing median overall survival in the picoplatin Phase 2 trial w
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 ... Administration (FDA) warned against the use of power ... and fibroid removal surgeries, insurer UnitedHealthCare is poised ... use of those devices. In a notification sent ... beginning in April, it would require pre-authorization for ...
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... of Idoll Magazine, a medium for the model agency ... can find, and buy Mango, Passion Fruit, Pink Grapefruit, ... March 3rd, 2015, after 1pm. , At a cost ... has recently came under fire by announcing the brands ...
(Date:3/2/2015)... Gummy smile reduction expert, Dr. Alex ... involve one or several procedures to reduce the appearance of ... a more even gum line. Dr. Farnoosh is the creator ... can permanently lighten discolored or naturally dark gums. , ... personalized treatment plan to address a patient’s specific needs based ...
(Date:3/2/2015)... Minnetonka, MN (PRWEB) March 02, 2015 ... accredited temperature calibration for Secondary Standard Platinum ... (RTDs) in 5 business days or less . ... is NVLAP ® Accredited (Lab Code 200706-0), ... NIST traceability. Temperature range is -196°C to ...
(Date:3/2/2015)... Over the last five years the ultrasound market ... expand their geographic presence and achieve economies of scale. ... billion by 2019 at CAGR of 5.1% from 2014 ... Canada and a major part of Europe are mature ... Asia-Pacific including China and India, Latin America and the ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3
... a company developing breakthrough molecular imaging agents ... announced today that the United States Patent ... 7,438,891, covering methods of imaging cardiovascular plaque ... patent, exclusively licensed from the Massachusetts General ...
... Increased 2% and Increased 1% Excluding the Impact of Foreign ... Decreased 7% and Decreased 1% Excluding the Impact of Foreign ... Increase Led by Growth in Excess of 10% for Prevnar, ... Jan. 26 Wyeth (NYSE: WYE ) today ...
... Saint Joseph,s Health System announced,that it has launched ... a,non-profit training center for robotic surgical teams from around ... Thoracic Surgeons (STS) annual,meeting in San Francisco. , ... to patients from robotic-assisted,surgery since we began our program ...
... To Stay Happy and Healthy This WinterSAN JOSE, Calif., ... avoiding the "winter blues" is to set small goals, ... and exercising, for a well-rounded approach to life. This ... Day of the Year," January 26, 2009, designated by ...
... Jan. 26 Concentric Medical, Inc., the global leader ... today announced that the company,s Merci Retrieval System(TM) has ... in August 2004. The Merci Retrieval System is ... to remove blood clots from patients suffering an ischemic ...
... Internal Manufacturing Scale-Up Underway to Support Increased Product ... (OTC Bulletin Board: BLFS), a leading developer and ... media products for cells, tissues, and organs, today ... full year 2008 and also the receipt of ...
Cached Medicine News:Health News:FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 3Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 4Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 5Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 6Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 7Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 8Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 9Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 10Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 11Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 12Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 13Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 14Health News:Saint Joseph's Launches International College of Robotic Surgery 2Health News:Natural Solutions for the Most Depressing Day of the Year 2Health News:Natural Solutions for the Most Depressing Day of the Year 3Health News:Natural Solutions for the Most Depressing Day of the Year 4Health News:Natural Solutions for the Most Depressing Day of the Year 5Health News:Concentric Medical Reaches Important Stroke Milestone 2Health News:Concentric Medical Reaches Important Stroke Milestone 3Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 2Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 3
(Date:3/2/2015)...   Oriel STAT A MATRIX announces ... most critical compliance and performance issues in the ... are experiencing an industry-transforming level of demand and ... global supply chains are negatively impacting product quality ... regulators are increasing compliance requirements, scrutiny, and enforcement. ...
(Date:3/2/2015)... 2, 2015  Akron Children,s Hospital has been designated ... American College of Radiology (ACR), making it the first ... second children,s hospital in the United States ... "Earning recognition from the ACR as a DICOE provides ... level compared with national benchmarks," says Dr. Michael ...
(Date:3/2/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, ... Allowance from the U.S. Patent and Trademark Office ... Compositions and methods to improve the therapeutic benefit ...
Breaking Medicine Technology:Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 2Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 3DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 4
... NEW YORK, March 21, 2011 The Alzheimer,s Drug ... grant of $170,750 to ADispell Inc. to develop small ... loss that occurs with Alzheimer,s Disease. ... licensed technology from Cornell University to develop neuroprotective drug ...
... LLC , ( www.curemark.com ), a drug research and development ... the company has completed its targeted enrollment of Phase III ... Curemark has reached its targeted enrollment for the study ... CM-AT Phase III trial at 18 sites across the country. ...
Cached Medicine Technology:Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease 2Curemark Completes Enrollment of Phase III Autism Trials 2
... Trellis Infusion Catheter enables the physician to ... fluid, and disperse the agent by means ... Trellis is a multi-lumen catheter with two ... and infusion holes located between these balloons. ...
... OptiEdge offers design innovations that ensure outstanding ... handling. The biostable acrylic material of the ... the patented OptiEdge is designed to both ... of contact with the posterior capsule; and ...
... posterior chamber lenses are optical implants for ... in the visual correction of aphakia in ... The optical portion consists of a high ... have biconvex optics and supporting haptics of ...
... an intraocular lens that doesn't stop ... natural human lens, the new ACRYSOF® ... high-energy blue light. But while it ... your patient's view. That's just as ...
Medicine Products: